FK506 attenuates developing and established joint inflammation and suppresses interleukin 6 and nitric oxide expression in bacterial cell wall induced polyarthritis

Journal of Rheumatology

Volumn 27, Issue 1, 2000, Pages 190-199

  Fuseler, John W ^a   Hearth Holmes, Michelene ^a   Grisham, Matthew B ^a   Kang, David ^a   Laroux, F Stephen ^a   Wolf, Robert E ^a  

^a LOUISIANA STATE UNIV MEDICAL CENTER   (United States)

Author keywords

Experimental arthritis; FK506 (tacrolimus); Interleukin 6; Nitric oxide

Indexed keywords

CYTOKINE; DEXAMETHASONE; INTERLEUKIN 6; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; TACROLIMUS;

ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; BACTERIAL CELL WALL; CONTROLLED STUDY; DRUG EFFECT; EXPERIMENTAL MODEL; FEMALE; INFLAMMATION; NONHUMAN; POLYARTHRITIS; PRIORITY JOURNAL; RAT; RHEUMATOID ARTHRITIS;

ANIMALS; ARTHRITIS; BACTERIAL PROTEINS; FEMALE; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN-6; NITRIC OXIDE; RATS; RATS, INBRED LEW; STREPTOCOCCUS; TACROLIMUS;

EID: 0033979915     PISSN: 0315162X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (60)

1. Harris ED. Rheumatoid arthritis. Pathophysiology and implications for therapy. N Eng J Med 1990;322:1277-89.
2. Cush JJ, Lipsky PE. Cellular basis for rheumatoid inflammation. Clin Orthop Rel Res 1991;265:9-22.
3. Greenwald RA. Oxygen radicals, inflammation and arthritis: pathophysiological considerations and implications for treatment. Semin Arthritis Rheum 1991;20:219-40.
4. Eastgate JA, Symons JA, Wood NC, Capper SJ, Duff GW. Plasma levels of interleukin-1-alpha in rheumatoid arthritis. Br J Rheumatol 1991;30:295-7.
5. Ardend WP, Dayer J-M. Inhibition of the production of and effects of interleukin-1 and tumor necrosis factor α in rheumatoid arthritis. Arthritis Rheum 1995;38:151-60.
6. van Leeuwen MA, Westra J, Limberg PC, van Riel PLCM, van Rijswijk MH. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid synovial fluid. Ann Rheum Dis 1995;54:33-8.
7. Ueki Y, Miyake S, Tominaga Y, Eguchi K. Increased nitric oxide levels in patients with rheumatoid arthritis. J Rheumatol 1996;23:230-6.
8. Dasgupta B, Corkill M, Kirkham B, Gibson T, Panayi G. Serial estimation of interleukin 6 as a measure of systemic disease in rheumatoid arthritis. J Rheumatol 1992;19:22-5.
9. Kino T, Hatanaka H, Miyata S, et al. FK506, a novel immunosuppressant isolated from a Streptomyces. II. Immunosuppressive effect of FK506 in vitro. J Antibiot (Tokyo) 1987;40:1256-65.
10. Todo S, Ueda Y, Demetrius JA, et al. Immunosuppression of canine, monkey and baboon allografts by FK506: with special references to synergism with other drugs and to tolerate induction. Surgery 1988;104:239-49.
11. Hooks MA. Tacrolimus, a new immunosuppressant - a review of the literature. Pharmacother 1994;28:501-11.
12. Inamura N, Hashimoto M, Nakahara K, Aoki H, Yamagugchi I, Kohsaka M. Immunosuppressive effect of FK506 on collagen-induced arthritis in rats. Clin Immunol Immunopathol 1988;46:82-90.
13. Takagishi K, Yamamotoi M, Nishimura A, et al. Effect of FK-506 on collagen arthritis in mice. Transplant Proc 1989;21:1053-5.
14. Aiko S, Conner EM, Fuseler JW, Grisham MB. Effect of cyclosporin or FK506 in chronic colitis. J Pharmacol Exp Ther 1997;280:1-10.
15. Yoshimura N, Matisu S, Hamashima T, Oka T. Effect of a new immunosuppressive agent, FK506, on human lymphocyte responses in vitro. II. Inhibition of the production of IL-1 and γIFN, but not B cell-stimulating factor 2. Transplantation 1989;47:356-9.
16. Nelson PA, Kawamura A, Akselband Y, Peattie DA, Aldape RA, Harding MW. Effect of immunosuppressive drugs on cytokine gene transcription studied by message amplification phenotyping (MAPPing) polymerase chain reaction. Transplant Proc 1991;23:2867-9.
17. Wang SC, Morel PA, Wang Q, Jordan ML, Simmons RL, Tweardy DJ. A dual mechanism of immunosuppression by FK506. Transplantation 1993;56:978-85.
18. Keicho N, Sawada S, Kitamura K, Yotsumoto H, Takaku F. Effects of an immunosuppressant, FK506, on interleukin 1α production by human macrophages and a macrophage-like cell line, U937. Cell Immunol 1991;132:285-94.
19. Hattori Y, Nakanishi N. Effects of cyclosporin A and FK506 on nitric oxide and tetrahydrobiopterin synthesis in bacterial lipopolysaccharide treated J774 macrophages. Cell Immunol 1995;165:7-11.
20. Sugimaya E. Suzuki H, Tunru IS, Yamashita N, Hori T, Kobayashi M. FK506, an immunosuppressant, partially inhibits interleukin-6 production by adherent rheumatoid synovial cells. J Rheumatol 1994;21:1597-601.
21. Han C-W, Imamura M, Hashino S, et al. Differential effects of the immunosuppressants cyclosporin A, FK506 and MK2210 on cytokine gene expression. Bone Marrow Transplant 1995;15:733-9.
22. Fuseler JW, Conner EM, Davis JM, Wolf RE, Grisham MB. Cytokine and nitric oxide production in the acute phase of bacterial cell wall-induced arthritis. Inflamm 1997;21:113-31.
23. Wilder RL. Streptococcal cell wall-induced polyarthritis in rats. In: Greenwald RA, Diamond H, editors. Handbook of animal models for the rheumatic diseases. Boca Raton: CRC Press; 1988;33-44.
24. Dabbagh AJ, Blake DR, Morris CJ. Effect of iron complexes on adjuvant arthritis. Ann Rheum Dis 1992;51:516-21.
25. O'Byrne EM, Roberts ED, Rubin AS, et al. Lactobacillus casei-induced polyarthritis in Lewis rats: histopathological scoring system for evaluation of anti-rheumatic drugs. Agents Actions 1991;34:239-41.
26. Ruff MR, Gifford GE. Tumor necrosis factor. In: Pick E, editor. Lymphokine reports. New York: Academic Press; 1981;235-75.
27. Frei K, Leist TP, Meager A, et al. Production of B cell stimulatory factor-2 and interferon-γ in the central nervous system during viral meningitis and encephalitis. Evaluation in a murine model infection and in patients. J Exp Med 1988;168:449-53.
28. Mosmann T. Rapid colorimetric assay for cellular growth and survival: application to proliferation and cytotoxic assays. J Immunol Methods 1988;65:55-63.
29. Grisham MB, Johnson GG, Gautreaux MD, Berg RD. Measurement of nitrate and nitrite in extracellular fluid: a window to systemic nitric oxide determination. Methods: Methods Enzymol 1995;7:84-90.
30. Sacerdote P, Carrabba M, Galante A, Pisati R, Manfredi B, Panerai AE. Plasma and synovial fluid interleukin-1, interleukin-6, and substance-P concentrations in rheumatoid arthritis patients: effect of the nonsteroidal antiinflammatory drugs indomethacin, diclofenac and naproxen. Inflamm Res 1995;44:486-90.
31. van Leeuwen MA, Westra J, Limberg PC, van Riel PLCM, van Rijswijk MH. Interleukin-6 in relation to other proinflammatory cytokines, chemotactic activity and neutrophil activation in rheumatoid fluid. Ann Rheum Dis 1995;54:33-8.
32. Tanabe M, Ochi T, Tomaita T, et al. Remarkable elevation of interleukin-6 and interleukin-8 in bone marrow serum of patients with rheumatoid arthritis. J Rheumatol 1994;21:830-5.
33. Firestein GS. Rheumatoid arthritis and pannus. In: Klippel JH, Dieppe P, editors. Rheumatology. London: Gower Publications, Mosby-Year Book, Europe Ltd.; 1994;3:1-30.
34. Rao A. NFATp, a cyclosporin-sensitive transplantation factor implicated in cytokine gene induction. J Leukoc Biol 1995;57:536-42.
35. Fealy MJ, Most D, Huie P, et al. Association of down-regulation of cytokine activity with rat hind limb allograft survival. Transplantation 1995;59:1475-80.
36. Palombella VJ, Conner EM, Fuseler JW, et al. Role of the proteasome and NF-KB in streptococcal cell wall-induced polyarthritis. Proc Natl Acad Sci USA 1998;95:15671-6.
37. Evans DM, Ralston SH. Nitric oxide and bone. J Bone Min Res 1996;11:300-5.
38. Stefanovic-Racic M, Stadler J, Evans CH. Nitric oxide and arthritis. Arthritis Rheum 1993;36:1036-44.
39. Kolb H, Kolb BV. Nitric oxide: a pathogenic factor in autoimmunity. Immunol Today 1992;13:157-60.
40. Collin-Osdoby P, Nickols GA, Osdoby P. Bone cell function, regulation, and communication: a role for nitric oxide. J Cell Biochem 1995;57:399-408.
41. Punjabi CJ, Laskin DL, Heck DE, Laskin JD. Production of nitric oxide by bone marrow cells. J Immunol 1992;149:2179-84.
42. Palmer RMJ, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature (Lond) 1988;333:664-6.
43. Wright CD, Mulsch A, Busse R, Oswald H. Generation of nitric oxide by human neutrophils. Biochem Biophys Res Commun 1990;160:813-9.
44. Stadler J, Stefanovic-Racic M, Billiar TR, et al. Articular chondrocytes synthesize nitric oxide in response to cytokines and lipopolysaccharide. J Immunol 1991;147:3915-20.
45. Farrell AJ, Blake DR, Palmer RMJ, Moncada S. Increased concentrations of nitrite in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992;51:1219-22.
46. St. Clair EW, Wilkinson WE, Lang T, et al. Increased expression of blood mononuclear cell nitric oxide synthase type 2 in rheumatoid arthritis patients. J Exp Med 1996;184:1173-8.
47. McCartney-Frances N, Allen JB, Mizel DE, et al. Suppression of arthritis by an inhibitor of nitric oxide synthase. J Exp Med 1993;178:749-54.
48. Ialenti A, Moncada S, Di Rosa M. Modulation of adjuvant arthritis by endogenous nitric oxide. Br J Pharmacol 1993;110:701-6.
49. Stefanovic-Racic M, Mayers K, Meschter JW, Coffey JW, Hoffman RA, Evans C. N-monomethyl arginine, an inhibitor of nitric oxide synthase, suppresses the development of adjuvant arthritis in rats. Arthritis Rheum 1994;37:1062-9.
50. G-monomethyl-L-arginine. J Exp Med 1994;179:651-60.
51. Connor JR, Manning PT, Settle SL, et al. Suppression of adjuvant-induced arthritis by selective inhibition of inducible nitric oxide synthase. Eur J Pharmacol 1995;273:15-24.
52. Schreiber SL. Chemistry and biology of the immunophilins and their suppressive ligands. Science 1991;251:283-7.
53. Thomas AW, Bonham CA, Zeevi A. Mode of action of Tacrolimus (FK506): molecular and cellular mechanisms. Therap Drug Monitoring 1995;17:584-91.
54. Flanagan WF, Corthesy B, Bram RJ, Crabtree GR. Nuclear association of a T-cell transcription factor blocked by FK506 and cyclosporin A. Nature 1991;352:803-7.
55. Dawson TM, Steiner JP, Dawson VL, Dinerman JL, Uhl GR, Snyder SH. Immunosuppressant FK506 enhances phosphorylation of nitric oxide synthase and protects against glutamate neurotoxicity. Proc Natl Acad Sci USA 1993;90:9808-12.
56. Conde M, Andrade J, Bedoya FJ, Santa Maria C, Sobrino F. Inhibitory effects of cyclosporin A and FK506 on nitric oxide production by cultured macrophages. Evidence of a direct effect on nitric oxide synthase activity. Immunology 1995;84:476-81.
57. Tai PK, Albers MW, Chang H, Faber LE, Schreiber SL. Association of a 59-kilodalton immunophilin with the glucocorticoid receptor complex. Science 1992;256:1315-8.
58. Ray A, LaForge KS, Sehgal PB. On the mechanism for efficient repression of the interleukin-6 promoter by glucocorticoids: enhancer, TATA box, and RNA start site (lnr motif) occlusion. Mol Cell Biol 1990;10:5736-46.
59. Guyer PM, Girard MT, Morganelli PM, Manganiello PD. Glucocorticoid effect on the production and actions of immune cytokines. J Steroid Biochem 1988;30:89-93.
60. Radomski MW, Palmer RM, Moncada S. Glucocorticoids inhibit the expression of an inducible, but not the constitutive, nitric oxide synthase in vascular endothelial cells. Proc Natl Acad Sci USA 1990;87:10043-7.